Milestone Pharmaceuticals Inc
NASDAQ:MIST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Milestone Pharmaceuticals Inc
NASDAQ:MIST
|
CA |
|
Enstar Group Ltd
NASDAQ:ESGR
|
BM |
Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 29 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Milestone’s lead product candidate is etripamil. The etripamil is a novel, potent and short-acting calcium channel blocker that has been designed rapid-onset nasal spray, which is self-administered by patients. The firm is developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation (AF) and rapid ventricular rate, and other cardiovascular indications.
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 29 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Milestone’s lead product candidate is etripamil. The etripamil is a novel, potent and short-acting calcium channel blocker that has been designed rapid-onset nasal spray, which is self-administered by patients. The firm is developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation (AF) and rapid ventricular rate, and other cardiovascular indications.
Approval: CARDAMYST (etripamil nasal spray) received FDA approval for conversion of PSVT to normal sinus rhythm in adults; product began retail distribution in late January and promotional launch in mid-February.
Launch early read: Sales force of ~60 reps targeting ~10,000 providers; in the first month of promotion there were over 150 prescriptions filled from more than 100 unique prescribers, mostly new patient starts.
Coverage & access: No broad contracted coverage yet; reimbursement requires prior authorizations/medical exceptions in many cases, but Milestone has patient assistance, co-pay support and reimbursement services active to help fill scripts.
Finances & runway: Reported pro forma cash of approximately $200 million (Dec 31, 2025 cash $106M plus January 2026 RTW royalty sale and subsequent financings); company expects operating runway into late 2027.
Commercial expectations: Management expects meaningful coverage and prescription growth over the course of 2026 with more material progress in the back half of the year; Medicare contracting expected to take longer (guidance toward 2027).
